Page 6 - Repurchase Offer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Santhera Pharmaceuticals Holding AG: Santhera Announces Settlement of Exchange Offer and Issuance of New Senior Unsecured Convertible Bonds due 2024 Pratteln, Switzerland, s the settlement of the e . Santhera Pharmaceuticals Holding AG is settling today its offer to exchange its outstanding CHF 60 million 5% Convertible Bonds due 2022 (the 2017/22 Bonds) on the terms set out in the Notice of Repurchase Offer dated March 25, 2021 (the Exchange Offer). Upon settlement, 2017/22 Bonds in the aggregate principal amount of CHF 15,155,000 remain in circulation. Santhera will issue today Senior ...

More from AP

By Notice of Repurchase Offer dated March 25, 2021 (the Notice), Santhera Pharmaceuticals Holding AG announced an offer to exchange its outstanding CHF 60 million 5% Convertible Bonds due 2022 (the 2017/22 Bonds) on the terms set out in the Notice (the Exchange Offer). The Exchange Offer was accepted by bondholders with respect to 2017/22 Bonds with an aggregate principal amount of CHF 44,845,000, corresponding to 74.7% of all 2017/22 Bonds in circulation. S ettlement Santhera has decided to settle the Exchange Offer on May 4, 2021. The Exchange Offer will be settled via the banking s...

By Notice of Repurchase Offer dated March 25, 2021 (the Notice), Santhera Pharmaceuticals Holding AG announced an offer to exchange its outstanding CHF 60 million 5% Convertible Bonds due 2022 (the 2017/22 Bonds) on the terms set out in the Notice (the Exchange Offer). The Exchange Offer was accepted by bondholders with respect to 2017/22 Bonds with an aggregate principal amount of CHF 44,845,000, corresponding to 74.7% of all 2017/22 Bonds in circulation. S ettlement Santhera has decided to settle the Exchange Offer on May 4, 2021. The Exchange Offer will be settled via the banking s...

Santhera Pharmaceuticals Holding AG: Santhera Reports 2020 Annual Results 4 this statement. CHF 67.7 20 as the basis for future growth S Pratteln, Switzerland, Company 20 lead uchenne muscular dystrophy (D . "Santhera started 2021 with the strong foundation of a refreshed clinical and operational strategy focused on vamorolone, which we believe can provide significant value to patients, caregivers, and ultimately shareholders. It represents the key foundation for the future of Santhera, which continues to focus on Duchenne muscular dystrophy (DMD) and other rare diseases.," said Dario E...